{"id":1000642,"date":"2026-09-04T08:12:34","date_gmt":"2026-09-04T12:12:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/"},"modified":"2026-09-04T08:12:34","modified_gmt":"2026-09-04T12:12:34","slug":"iovance-biotherapeutics-to-present-at-upcoming-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/","title":{"rendered":"Iovance Biotherapeutics to Present at Upcoming Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN CARLOS, Calif., Sept.  04, 2026  (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">Wells Fargo 21st Annual Healthcare Conference<br \/>Fireside Chat: September 10, 2026, at 11:00 a.m. ET<br \/>Boston, MA<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:left\">H.C. Wainwright 28th Annual Global Investment Conference<br \/>Presentation: September 15, 2026, at 4:00 p.m. ET<br \/>New York, NY<\/li>\n<\/ul>\n<p>The live and archived webcast will be available at <a href=\"https:\/\/ir.iovance.com\/news-events\/events-presentations\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.iovance.com\/news-events\/events-presentations<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Iovance Biotherapeutics, Inc.\u00a0<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">Iovance Biotherapeutics<\/a>, Inc. \u00a0is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi<sup>\u00ae<\/sup> (lifileucel) is the first\u00a0FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The\u00a0<a href=\"https:\/\/www.iovance.com\/our-science\/til-platform\/\" rel=\"nofollow\" target=\"_blank\">Iovance TIL platform<\/a>\u00a0spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized\u00a0U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>Amtagvi\u00ae and its accompanying design marks, Proleukin<sup>\u00ae<\/sup>, Iovance<sup>\u00ae<\/sup>, and IovanceCares\u2122\u00a0are trademarks and registered trademarks of\u00a0Iovance Biotherapeutics, Inc.\u00a0or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.<\/p>\n<p>Information on Iovance\u2019s broad, industry-leading patent portfolio is available on the Intellectual Property page on\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain matters discussed in this press release are \u201cforward-looking statements\u201d of Iovance Biotherapeutics, Inc. (hereinafter referred to as the \u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Without limiting the foregoing, we may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cachievable,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\u00a0<\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>\n        <a href=\"mailto:IR@iovance.com\" rel=\"nofollow\" target=\"_blank\">IR@iovance.com<\/a><br \/>\n        <br \/>650-260-7120\u00a0ext. 150<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>\n        <a href=\"mailto:PR@iovance.com\" rel=\"nofollow\" target=\"_blank\">PR@iovance.com<\/a>\u00a0<br \/>650-260-7120\u00a0ext. 150<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDhmYTFmZGUtNmFlMy00MDk4LThkZTktYzU0NTE4ZGViNDE2LTEwMzA3NjktMjAyNi0wOS0wNC1lbg==\/tiny\/Iovance-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global Investment ConferencePresentation: September 15, 2026, at 4:00 p.m. ETNew York, NY The live and archived webcast will be available at https:\/\/ir.iovance.com\/news-events\/events-presentations. About\u00a0Iovance Biotherapeutics, Inc.\u00a0 Iovance Biotherapeutics, Inc. \u00a0is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi\u00ae (lifileucel) is the first\u00a0FDA-approved, one-time &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iovance Biotherapeutics to Present at Upcoming Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1000642","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iovance Biotherapeutics to Present at Upcoming Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iovance Biotherapeutics to Present at Upcoming Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global Investment ConferencePresentation: September 15, 2026, at 4:00 p.m. ETNew York, NY The live and archived webcast will be available at https:\/\/ir.iovance.com\/news-events\/events-presentations. About\u00a0Iovance Biotherapeutics, Inc.\u00a0 Iovance Biotherapeutics, Inc. \u00a0is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi\u00ae (lifileucel) is the first\u00a0FDA-approved, one-time &hellip; Continue reading &quot;Iovance Biotherapeutics to Present at Upcoming Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T12:12:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iovance Biotherapeutics to Present at Upcoming Conferences\",\"datePublished\":\"2026-09-04T12:12:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/\"},\"wordCount\":562,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/\",\"name\":\"Iovance Biotherapeutics to Present at Upcoming Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=\",\"datePublished\":\"2026-09-04T12:12:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iovance Biotherapeutics to Present at Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iovance Biotherapeutics to Present at Upcoming Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Iovance Biotherapeutics to Present at Upcoming Conferences - Market Newsdesk","og_description":"SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global Investment ConferencePresentation: September 15, 2026, at 4:00 p.m. ETNew York, NY The live and archived webcast will be available at https:\/\/ir.iovance.com\/news-events\/events-presentations. About\u00a0Iovance Biotherapeutics, Inc.\u00a0 Iovance Biotherapeutics, Inc. \u00a0is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi\u00ae (lifileucel) is the first\u00a0FDA-approved, one-time &hellip; Continue reading \"Iovance Biotherapeutics to Present at Upcoming Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-04T12:12:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iovance Biotherapeutics to Present at Upcoming Conferences","datePublished":"2026-09-04T12:12:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/"},"wordCount":562,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/","name":"Iovance Biotherapeutics to Present at Upcoming Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=","datePublished":"2026-09-04T12:12:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTQyOSM3ODE3OTg3IzIwMTkxOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-at-upcoming-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iovance Biotherapeutics to Present at Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1000642"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000642\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1000642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1000642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1000642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}